Skip to main content Deutsch

News

News

Philipp Staber and Tea Pemovska will give lectures on precision medicine at the "Functional Precision Medicine for Blood Cancer Workshop and Symposium 2022", organized by the University of Helsinki, Institute for Molecular Medicine Finland (FIMM) and HUS Helsinki University Hospital on 06.09.2022.

Tea Pemovska receives the 2nd prize of the Dora Brücke-Teleky Award for her research project "Metabolic drug survey highlights cancer cell dependencies and vulnerabilities", published in Nature Communications. The Dora Brücke-Teleky Award honors outstanding publications by postdocs at MedUni Vienna.

» Dora Brücke-Teleky Award

Carmen Schweicker receives the Young Pharma Award 2022 for her master's thesis entitled "Role of PU.1 non-coding transcripts in physiological hematopoiesis and leukemia". The award recognizes innovative research projects with practical benefits and aims to build a bridge between students and the Austrian pharmaceutical industry.

» Young Pharma Award 2022

Tea Pemovska and Christoph Kornauth are awarded for their outstanding research project entitled "Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders" and receive a research grant from the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital!

» CCC Forschungsförderung

Personalized Medicine in Hematology" tumour board: new opportunities for patients with relapsed haematological cancers.
The central topic of the "Personalized Medicine in Hematology" tumour board is the treatment of patients with leukaemias and lymphomas. The focus of this tumour board is the creation of treatment plans that are individually adapted to patients - in other words, a precision medicine approach to treatment. What is new internationally about the approach at MedUni Vienna and Vienna General Hospital is that functional assays are also carried out in addition to genetic characterization of the tumour.

» Further Informations

Roche Science Award 2019 to Philipp Staber and Christoph Kornauth.
The study "Next generation personal hematology" (led by Staber) was selected from around 40 national academic research projects by an independent jury of experts at the 4th Roche Science Talk on November 20, 2019 in Vienna.

» Further Informations

Philipp Staber receives Celgene Future Leader Award.
Hemato-oncologist Philipp Staber, Division of Hematology and Hemostaseology at MedUni Vienna and Vienna General Hospital and member of the Comprehensive Cancer Center (CCC) of both institutions, was the first European to receive the Celgene Future Leader Award. The award recognizes Staber's contribution to the further development of functional precision medicine in the field of tumour diseases of the blood and lymphatic system. The award of 10,000 dollars was presented in early December at the 2018 Annual Meeting of the American Society of Hematology (ASH).

» Further Informations

Viennese researcher initiates international consensus criteria for the first time.
A consensus paper for T-prolymphocytic leukemia (T-PLL) has been drawn up on the initiative of Associate Professor Dr. Philipp Staber, Department of Internal Medicine I, Vienna. For the first time, a globally standardized approach to diagnosis and therapy assessment is now possible.

» Further Informations

New research successes in chronic lymphocytic leukemia (CLL).
New research findings, innovative drugs and new treatment options combined with proven therapies have led to an enormous increase in the chances of survival and recovery for many tumor entities. Diagnoses can also be made earlier and faster, meaning that more and more types of cancer are becoming chronic diseases and therefore easily treatable.

» Further Informations

New hope for cancer patients through personalized medicine.
In Austria, around 40,000 people are diagnosed with cancer every year. In a metastasized, incurable stage, therapies aim to improve quality of life or prolong overall survival. In some cases, however, all conventional therapies fail, so that disease control is no longer possible and the tumor disease continues to progress. Researchers at MedUni Vienna's Comprehensive Cancer Center (CCC) and Vienna General Hospital have now been able to show that precision medicine opens up new avenues here. They analyzed the molecular biological characteristics of more than 500 cancer patients for whom all standard palliative therapies had already been exhausted. Based on the results, the experts were able to offer a new targeted therapy option - based on the individual molecular profile - to 55 percent of the patients who had exhausted their treatment.

» Further Informations